Medical News

RSS

EMBL scientists identify genes involved in human cell division

Name a human gene, and you'll find a movie online showing you what happens to cells when it is switched off. This is the resource that researchers at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and their collaborators in the Mitocheck consortium are making freely available, as the result of a study in which they have identified the genes involved in mitosis - the most common form of cell division - in humans.

1 Apr 2010

Cord Blood America signs License and Cooperation Agreement with AXM Pharma in China

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has signed a License and Cooperation Agreement for the processing and storage of umbilical cord blood in China with AXM Pharma, Inc.

1 Apr 2010

A roundup of health overhaul fack-checking

Will all Americans get health coverage as good as lawmakers' insurance under the overhaul, as Democrats pledged? Apparently so. Even though most federal workers will maintain their federally employee's benefits, lawmakers will have to sign up for insurance plans through the new, state-run exchanges offered through the health legislation (Barry, 3/31).

1 Apr 2010

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.

1 Apr 2010

BioCision, Biohit announce co-promotion program

BioCision LLC today announced that it has agreed to a co-promotion program with Biohit Inc.. Biohit's ErgoTube microcentrifuge tubes will now be branded and sold by both Biohit Inc. and BioCision. In addition, Biohit Inc. will cross-promote BioCision's highly thermo-conductive CoolRack microfuge tube racks for use in combination with ErgoTubes.

31 Mar 2010

Collegium Pharmaceutical receives USPTO notice of allowance for novel formulation of milnacipran

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Modified Release Compositions of Milnacipran", US Patent Application Number 12/211,780. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

31 Mar 2010

ChromaDex records revenue of $5.78M for 2009

ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.

31 Mar 2010

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its C. albicans PNA FISH® and C. albicans/C. glabrata PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

31 Mar 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

Birner Dental Management Services' 2009 net income up 7.5%

Birner Dental Management Services, Inc., operators of PERFECT TEETH® dental practices, announced results for the year and quarter ended December 31, 2009. For the year ended December 31, 2009, revenue increased $557,000, or 0.9%, to $59.6 million. The Company's earnings before interest, taxes, depreciation, amortization and non-cash expense associated with stock-based compensation ("Adjusted EBITDA") increased $101,000, or 1.5%, to $6.9 million.

31 Mar 2010

Accellent's net sales for fourth-quarter of 2009 decrease by 12.1%

Accellent Inc., a wholly owned subsidiary of Accellent Holdings Corp., today announced results for its fiscal fourth quarter and full year ended December 31, 2009.

31 Mar 2010

Changes in daily behavior can influence remembering to take daily medication

For many people, remembering to take a daily medication can be the difference between life and death. Yet, people forget all the time. Now a landmark study from North Carolina State University has found that changes in daily behavior have a significant effect on whether we remember to take our medication - and that these changes influence older and younger adults differently. That's good news, because it means there's something we can do about it.

31 Mar 2010

High-fructose corn syrup makes rats fat: Princeton University study questioned

"HFCS makes rats fat? I can hardly believe that Princeton sent out a press release yesterday announcing the results of this rat study. The press release says: "Rats with access to high-fructose corn syrup gained significantly more weight than those with access to table sugar, even when their overall caloric intake was the same."

31 Mar 2010

Funds raised at CASMA's spring conference to benefit The Montréal Children's Hospital

Mondial Assistance and the Computerized Airline Sales and Marketing Association announced today that a fundraiser held during a reception at CASMA's spring conference in Montréal raised enough money to purchase a saturation/end tidal carbon dioxide monitor for the Department of Anesthesia at The Montréal Children's Hospital.

31 Mar 2010

CAMH embarks on next phase of landmark redevelopment project

The Centre for Addiction and Mental Health is making history. On April 6, CAMH is breaking ground on the next phase of its landmark redevelopment project, transforming the site of what was originally the 1850 Provincial Lunatic Asylum into a modern, welcoming 'urban village' in the heart of Queen Street West. Nothing quite like this has ever been done before.

31 Mar 2010

Company affiliation is the greatest driver of farm-to-farm disease transmission risk: Study

A new study by researchers at the Johns Hopkins Bloomberg School of Public Health examines the potential influence that the business connections between broiler chicken growers may have on the transmission of avian influenza, H5N1. According to the study, the risk of between-farm transmission is significantly greater among farms within the same company group than it is between farms with different company affiliation.

31 Mar 2010

Omega Healthcare Investors agrees to sell common stock under equity distribution agreement with BofA Merrill Lynch

Omega Healthcare Investors, Inc. today announced that it has agreed to sell shares of its common stock having an aggregate offering price of $33.3 million pursuant to a terms agreement entered into under the equity distribution agreement, dated June 12, 2009, between the Company and BofA Merrill Lynch in connection with the company's previously reported $100 million Equity Shelf Program.

31 Mar 2010

BBSRC, NSF to hold intensive week long facilitated workshop to enhance photosynthesis

Leading bioscience funding bodies in the UK and USA announce plans to promote scientific proposals in the potentially transformational area of enhanced photosynthesis.

31 Mar 2010

Medical News

EMBL scientists identify genes involved in human cell division

Cord Blood America signs License and Cooperation Agreement with AXM Pharma in China

A roundup of health overhaul fack-checking

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

BioCision, Biohit announce co-promotion program

Collegium Pharmaceutical receives USPTO notice of allowance for novel formulation of milnacipran

ChromaDex records revenue of $5.78M for 2009

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

RXi Pharmaceuticals reports net loss of 28% for 2009

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

Birner Dental Management Services' 2009 net income up 7.5%

Accellent's net sales for fourth-quarter of 2009 decrease by 12.1%

Changes in daily behavior can influence remembering to take daily medication

High-fructose corn syrup makes rats fat: Princeton University study questioned

Funds raised at CASMA's spring conference to benefit The Montréal Children's Hospital

CAMH embarks on next phase of landmark redevelopment project

Company affiliation is the greatest driver of farm-to-farm disease transmission risk: Study

Omega Healthcare Investors agrees to sell common stock under equity distribution agreement with BofA Merrill Lynch

BBSRC, NSF to hold intensive week long facilitated workshop to enhance photosynthesis

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News